Screener
Zevra Therapeutics, Inc. ZVRA Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Current portion of operating lease liabilities | 626 | 419 |
| Current portion of discount and rebate liabilities | 11,777 | 12,188 |
| Current portion of income tax payable | 20,844 | 13,710 |
| Other current liabilities | 1,423 | 1,362 |
| Total current liabilities | 48,632 | 39,277 |
| Long-term debt | — | 61,928 |
| Warrant liability | 13,165 | 9,575 |
| Income tax payable | 7,206 | 7,029 |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s accrued expenses?
- Zevra Therapeutics, Inc. (ZVRA) reported accrued expenses of $1.42M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s accrued expenses changed year-over-year?
- Zevra Therapeutics, Inc.'s accrued expenses decreased by 79.3% year-over-year, from $6.87M to $1.42M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s accrued expenses has grown at a 51.3% compound annual growth rate (CAGR), from $172K to $1.36M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Zevra Therapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude